Opin vísindi

Positive airway pressure treatment affects respiratory symptoms and gastro-oesophageal reflux : the Icelandic Sleep Apnea Cohort Study

Positive airway pressure treatment affects respiratory symptoms and gastro-oesophageal reflux : the Icelandic Sleep Apnea Cohort Study


Titill: Positive airway pressure treatment affects respiratory symptoms and gastro-oesophageal reflux : the Icelandic Sleep Apnea Cohort Study
Höfundur: Emilsson, Össur Ingi
Aspelund, Thor   orcid.org/0000-0002-7998-5433
Janson, Christer
Benediktsdóttir, Bryndís
Juliusson, Sigurdur
Maislin, Greg
Pack, Allan I
Keenan, Brendan T
Gíslason, Þórarinn
Útgáfa: 2023-09
Tungumál: Enska
Umfang: 514493
Háskóli/Stofnun: Landspitali - The National University Hospital of Iceland
Svið: Health Sciences
Deild: Faculty of Medicine
Birtist í: ERJ Open Research; 9(5)
ISSN: 2312-0541
DOI: 10.1183/23120541.00387-2023
Efnisorð: Lungnalæknisfræði; Háls-, nef- og eyrnalækningar; Pulmonary and Respiratory Medicine
URI: https://hdl.handle.net/20.500.11815/4523

Skoða fulla færslu

Tilvitnun:

Emilsson , Ö I , Aspelund , T , Janson , C , Benediktsdóttir , B , Juliusson , S , Maislin , G , Pack , A I , Keenan , B T & Gíslason , Þ 2023 , ' Positive airway pressure treatment affects respiratory symptoms and gastro-oesophageal reflux : the Icelandic Sleep Apnea Cohort Study ' , ERJ Open Research , vol. 9 , no. 5 , 00387-2023 . https://doi.org/10.1183/23120541.00387-2023

Útdráttur:

AIM: To study the effect of positive airway pressure (PAP) treatment on nocturnal gastro-oesophageal reflux (nGOR) and respiratory symptoms among clinical obstructive sleep apnoea (OSA) patients. METHODS: 822 patients newly diagnosed with OSA referred for PAP treatment were recruited. 732 patients had a 2-year follow-up visit with continuous PAP compliance data (366 full PAP users, 366 partial/non-PAP users). They answered questionnaires, including reporting of nGOR, sleep and respiratory symptoms and general health. Patients with nGOR symptoms once a week or more were defined as "with nGOR". Those without nGOR symptoms and nGOR medication were defined as "no nGOR". Others were defined as "possible nGOR". RESULTS: At 2-year follow-up, PAP treatment among full users resulted in decreased nGOR (adjusted OR 0.58, 95% CI 0.40-0.86) and wheezing (adjusted OR 0.56, 95% CI 0.35-0.88) compared with partial/non-PAP users. Decreased nGOR, among both full and partial/non-users of PAP treatment, was associated with a decrease in productive morning cough (adjusted OR 4.70, 95% CI 2.22-9.99) and a decrease in chronic bronchitis (adjusted OR 3.86, 95% CI 1.74-8.58), but not decreased wheezing (adjusted OR 0.90, 95% CI 0.39-2.08). A mediation analysis found that PAP treatment directly led to a decrease in wheezing, not mediated through nGOR. Conversely, PAP treatment decreased productive cough mediated through a decrease in nGOR. CONCLUSION: In an unselected group of OSA patients, PAP treatment for 2 years was associated with a decrease in nGOR and respiratory symptoms. The PAP treatment itself was associated with less wheezing. A decrease in nGOR through PAP treatment was associated with a decrease in productive cough.

Athugasemdir:

Publisher Copyright: © The authors 2023.

Skrár

Þetta verk birtist í eftirfarandi safni/söfnum: